Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Drops By 39.8%

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 47,547 shares, a drop of 39.8% from the December 15th total of 78,920 shares. Based on an average daily trading volume, of 57,964 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the shares of the stock are short sold. Currently, 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 57,964 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Zacks Research raised shares of Silexion Therapeutics to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Litchfield Hills Research started coverage on Silexion Therapeutics in a research note on Monday, December 15th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Silexion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Stock Down 7.0%

NASDAQ:SLXN traded down $0.17 on Friday, hitting $2.27. The company had a trading volume of 36,498 shares, compared to its average volume of 55,522. Silexion Therapeutics has a 52 week low of $1.65 and a 52 week high of $51.75. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. The firm has a 50 day moving average of $2.50 and a two-hundred day moving average of $5.39.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.